# Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

> **NCT03732638** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1590 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03732638
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-14
- **Primary completion:** 2019-12-10
- **Final completion:** 2021-02-02
- **Target enrollment:** 1590 (ACTUAL)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732638, "Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03732638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*